ClinicalTrials.gg
CompletedNCT05549947Updated Apr 29, 2026

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

A Phase 2 interventional study of SHR-1819 and Placebo in Moderate to Severe Atopic Dermatitis, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 14
158 · median 159
Started
2022
with 1 other
Phase 2
6 of 14
1 open now
Registered
5th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

03

Conditions studied

  • Moderate to Severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily sign forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol;
  2. Age 18 to 75 years old (inclusive) at the time of signing the informed consent form, regardless of gender;
  3. Have atopic dermatitis at the time of screening (according to the 2014 American College of Dermatology Guidelines) and have a course of at least 1 year before screening;
  4. At the screening and baseline periods, EASI ≥ 16, IGA ≥ 3, BSA ≥ 10%;
  5. The average daily peak pruritus (itch) numerical evaluation scale (P-NRS) score for the first 7 days of randomization ≥ 4 points (at least 4 days of daily peak pruritus P-NRS scores need to be collected);
  6. According to the investigators, topical TCS treatment was poor or intolerant within 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Major surgeries are planned for the duration of the study;
  3. History of previous atopic corneal conjunctivitis involving the cornea;
  4. History of diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis;
  5. Subjects have had or are currently clinically significant diseases or abnormalities;
  6. Screening for people with a history of heavy alcohol consumption or substance abuse in the 3 months prior to screening;
  7. The drug has been used in the previous 6 months;
  8. Screening of subjects with within the first 5 years (except completely cured cervical cancer in situ and non- cutaneous squamous cell carcinoma or basal cell carcinoma);
  9. Other comorbid (or co-occurring) skin disorders may be affected in the study evaluation;
  10. Any cause that the researchers believe would prevent the participants from participating in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Treatment group A: SHR-1819

    Drug: SHR-1819

  • Experimental
    Treatment group B: SHR-1819

    Drug: SHR-1819

  • Experimental
    Treatment group C: SHR-1819

    Drug: SHR-1819

  • Placebo comparator
    Treatment group D: placebo

    Drug: Placebo

Interventions

  • Treatment group A: SHR-1819 injection dose 1; Treatment group B: SHR-1819 injection dose 2; Treatment group C:SHR-1819 injection dose 3.

  • DrugPlacebo

    Treatment group D: placebo

06

What researchers measure

Primary outcomes

  1. At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥ 75% from baseline)

    EASI sore use EASI scale

    Time frame: Up to 16 weeks

Secondary outcomes

  1. At week 16, the proportion of participants with an overall investigator assessment (IGA) score of 0 or 1 (0-4 scale) and a decrease of ≥ 2 points from baseline

    The overall degree of improvement was assessed using the IGA scale

    Time frame: Up to 16 weeks

  2. At week 16, the proportion of subjects whose IGA score decreased from baseline by ≥ 2 points

    The overall degree of improvement was assessed using the IGA scale

    Time frame: Up to 16 weeks

  3. At week 16, the proportion of subjects who achieved EASI-90 (EASI score ≥ 90% lower than baseline)

    The extent of area is assessed using the EASI scale

    Time frame: Up to 16 weeks

  4. At week 16, the percentage of subjects who achieved EASI-50 (EASI score ≥ 50% lower than baseline)

    The extent of area is assessed using the EASI scale

    Time frame: Up to 16 weeks

  5. At week 16, the weekly average of the daily peak itching (itch) digital evaluation scale (P-NRS) decreased from baseline by ≥ 4 points

    The extent of pruritus is assessed using the P-NRS scale

    Time frame: Up to 16 weeks

  6. At week 16, EASI is the percentage change from baseline and change

    The extent of area is assessed using the EASI scale

    Time frame: Up to 16 weeks

  7. At week 16, the atopic dermatitis score (SCORAD) was the percentage change from baseline and change

    The extent of lesions and pruritus is assessed using the SCORAD scale

    Time frame: Up to 16 weeks

  8. At week 16, atopic dermatitis affects the body surface area (BSA) as a percentage of the baseline change and change

    The BSA scale was used to assess improvement in lesion area

    Time frame: Up to 16 weeks

  9. At week 16, the Dermatological Quality of Life Scale (DLQI) score was a percentage change from baseline and change

    The quality of Life is assessed using the DLQI scale

    Time frame: Up to 16 weeks

  10. The incidence of adverse events ranged from the first dose to 24 weeks

    Assess the post-medication safety of subjects from the first dose to the time they exit the group

    Time frame: From the beginning of administration to the 24th week

  11. Concentration of SHR-1819 in serum

    Time frame: From the beginning of administration to the 24th week

  12. Changes of TARC/CCL17 in the serum

    Time frame: From the beginning of administration to the 24th week

  13. Changes of IgE in the serum

    Time frame: From the beginning of administration to the 24th week

  14. Changes of eotaxin-3 in the serum

    Time frame: From the beginning of administration to the 24th week

  15. Immunogenicity of SHR-1819

    Time frame: From the beginning of administration to the 24th week

07

Study locations

1 site
  • Huashan Sub-Hospital of Fudan University
    Shanghai, Shanghai Municipality 200040, China
08

References and documents

Publications

  • Gu C, Yin H, Yang B, Ji S, Bian K, Man X, Lu J, Sui D, Zhou Y, Cheng F, Xu A, Li X, Jiang M, Diao Q, Ji C, Shi T, Ding Y, Ren H, Li Y, Liu H, Meng Z, Feng P, Zhang S, Bai X, Li P, Dong Y, Liu S, Zhang C, Xu J. Anti-IL-4Ralpha antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study. BMC Med. 2026 May 28. doi: 10.1186/s12916-026-04952-3. Online ahead of print. PubMed 42210243 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2023, 11 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 22, 2022
StartActual
Oct 8, 2022
Primary completionActual
Sep 15, 2023
CompletionActual
Nov 23, 2023
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05549947
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Oct 8, 2022
Primary completion
Sep 15, 2023
Completion
Nov 23, 2023
Last update
Apr 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1819

Start the discussion